NCT05002816 is a Phase 1/Phase 2 clinical trial of Elotuzumab in Multiple Myeloma, sponsored by Yale University.

Who is sponsoring NCT05002816?

NCT05002816 is sponsored by Yale University.

What drugs are being tested in NCT05002816?

Interventions in NCT05002816: Elotuzumab, Belantamab mafodotin.

What condition does NCT05002816 study?

NCT05002816 studies Multiple Myeloma.

Is NCT05002816 still recruiting?

NCT05002816 is currently active, enrolled. Last updated 11 May 2026.

Last reviewed 2026-05-11 · How we verify

NCT05002816

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Active, enrolled Phase 1/Phase 2 Last updated 11 May 2026

What this trial tests

Phase 1/Phase 2 trial testing Elotuzumab in Multiple Myeloma in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 February 2022

Primary endpoint
22 January 2026

1 December 2026

Quick facts

Lead sponsor	Yale University
Phase	Phase 1/Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	21 February 2022
Primary completion	22 January 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Elotuzumab (elotuzumab) — full drug profile →
Belantamab mafodotin (BELANTAMAB MAFODOTIN) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Yale University

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum tolerated dose of elotuzumab in combination with belantamab mafodotin in subjects
Time frame: 28 days
Study patients will be enrolled and treated in cohorts of size 4 with maximum of 12 patients in the Phase I portion of the trial with possible dose de-escalation of belantamab mafodotin plus a fixed level of elotuzumab. Starting dose of belantamab mafodotin will be 1.9 mg/kg q4w. If the DLT rate hits de-escalation boundary (≥ 29.8%), four more patients will be enrolled for lower dose level with 1.
Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)
Time frame: 28 days
DLT is defined as Grade 3 or greater febrile neutropenia lasting \>48 h despite adequate treatment, Grade 4 thrombocytopenia less than 25 accompanied by clinically significant bleeding, any Grade 3 or greater non-hematologic toxicity (other than corneal events) which is more severe than expected for an individual agent or which does not resolve with appropriate supportive treatment within 48 hours

Sponsor's own description

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.
Xiao L, Zhang L, Guo C, Xin Q, et al · · 2024 · cited 37× · PMID 38923737 · DOI 10.1002/cac2.12579
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
Chu E, Wu J, Kang SS, Kang Y. · · 2023 · cited 28× · PMID 37754488 · DOI 10.3390/curroncol30090573
Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).
Lu J, Ding J, Liu Z, Chen T. · · 2022 · cited 14× · PMID 34981814 · DOI 10.3892/ijo.2022.5302
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Morè S, Offidani M, Corvatta L, Petrucci MT, et al · · 2023 · cited 13× · PMID 37296910 · DOI 10.3390/cancers15112948
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
McCurdy A, Visram A. · · 2022 · cited 8× · PMID 36417082 · DOI 10.1007/s11899-022-00682-4
SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy.
Li J, Fan T, Wang D, Xiao C, et al · · 2025 · cited 2× · PMID 40382610 · DOI 10.1186/s12943-025-02308-8
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024.
Gong X, Zhang L, He X, Yang J, et al · · 2024 · cited 2× · PMID 39075582 · DOI 10.1186/s13045-024-01575-0
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.
Parrondo RD, Das S, Sledge H, Bergsagel L, et al · · 2025 · PMID 40410136 · DOI 10.1038/s41408-025-01310-z

Verify or expand the search:

Other trials of Elotuzumab

Trials testing the same drug.

NCT06785415 — Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT06518551 — Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM · Phase 1, PHASE2 · recruiting
NCT06232707 — A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapse · Phase 3 · withdrawn
NCT06152575 — MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha · Phase 3 · recruiting
NCT06208150 — A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamet · Phase 3 · recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05002816 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 11 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05002816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing